Weight-Loss drug semaglutide put to the test on appetite control

NCT ID NCT05548647

Completed Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study looked at how a weekly injection of semaglutide (2.4 mg) affects appetite, eating behavior, and mood in 120 adults with obesity. All participants also received lifestyle counseling on diet and exercise. The goal was to see if semaglutide reduces calorie intake and improves feelings of fullness compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (a once-weekly injection for weight loss)
What this could lead to: If successful, this could confirm how semaglutide helps control appetite and eating habits, supporting its use as a long-term weight management tool.
What could go wrong: This is a completed Phase 4 trial, so results are already in. However, the findings may not apply to everyone, and semaglutide can cause side effects like nausea or vomiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Appetitive Behavior Body Weight Body Weight Changes Motor Activity Obesity obesity disorder Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

University of Pennsylvania Center for Weight and Eating Disorders

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.